HEALIUS LIMITED — Director's Dealing 2023

May 31, 2023

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maxine Jaquet
Date of last notice	1 March 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	30 May 2023
No. of securities held prior to change	368,017 Ordinary Shares 3,335,611 Options 41,066 Service Rights
Class	HLSAB Performance Rights
Number acquired	371,859
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued under the terms of the HLS FY23 Long -Term Incentive Plan approved at the FY22 AGM with performance hurdles to be measured over a three-year period commencing 1 July 2022.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

368,017 Ordinary Shares 3,335,611 Options No. of securities held after 41,066 Service Rights change 371,859 Performance Rights Nature of change Issued under the terms of the HLS FY23 Long -Term Incentive Example: on-market trade, off-market trade, Plan approved at the FY22 AGM with performance hurdles to exercise of options, issue of securities under be measured over a three-year period commencing from 1July dividend reinvestment plan, participation in buyback 2022.

Part 2 – Change of director’s interests in contracts Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where N/A prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date N/A was this provided?

Authorised by the Company Secretary.

Mary Weaver Company Secretary Date: 1 June 2023

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011